Name of this trial: Artemide-HCC01
What type of cancer is this for? Advanced Hepatocellular Cancer
Who is this trial for? Patients who have advanced kidney cancer that have not had prior treatment in advanced setting.
What biomarkers are involved? Central PD-L1 testing, however positivity not dependent on inclusivity
What is the National Clinical Trial #? NCT06921785
Brief summary of this trial: Phase 3, randomized, open-label, sponsor-blinded, study of rilvegostomig in combination with bevacizumab w/wo Tremelimumab, as 1L treatment in patients with advanced hepatocellular carcinoma.
Need to know: Randomized portion has 3 potential arms 1:1:1 randomization. Arm A: Tremelimumab/Rilvesgostomig/Bevacizumab, Arm B: Rilvesgostomig/Bevacizumab, Arm C: Bevacizumab/Atezolizumab (Standard of care arm)
Where is this trial available? The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065 or email [email protected]